Shares of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) have been assigned a consensus rating of “Buy” from the eight brokerages that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $32.80.
Several equities analysts have recently issued reports on EIGR shares. Wedbush reissued an “ourperform” rating and issued a $34.00 price objective on shares of Eiger BioPharmaceuticals in a report on Monday, August 14th. Piper Jaffray Companies reissued a “buy” rating and issued a $36.00 price objective on shares of Eiger BioPharmaceuticals in a report on Tuesday, August 15th. Zacks Investment Research cut Eiger BioPharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, August 16th. ValuEngine raised Eiger BioPharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Finally, Oppenheimer restated a “buy” rating and issued a $34.00 price target on shares of Eiger BioPharmaceuticals in a research note on Monday, September 25th.
Several institutional investors have recently made changes to their positions in EIGR. Sphera Funds Management LTD. increased its stake in shares of Eiger BioPharmaceuticals by 35.0% in the 3rd quarter. Sphera Funds Management LTD. now owns 520,269 shares of the biotechnology company’s stock valued at $5,723,000 after purchasing an additional 134,968 shares in the last quarter. P.A.W. Capital Corp purchased a new stake in Eiger BioPharmaceuticals during the 3rd quarter worth approximately $880,000. Hikari Power Ltd increased its stake in Eiger BioPharmaceuticals by 491.0% during the 2nd quarter. Hikari Power Ltd now owns 60,992 shares of the biotechnology company’s stock worth $482,000 after buying an additional 50,672 shares in the last quarter. Goldman Sachs Group Inc. purchased a new stake in Eiger BioPharmaceuticals during the 2nd quarter worth approximately $272,000. Finally, LMR Partners LLP purchased a new stake in Eiger BioPharmaceuticals during the 2nd quarter worth approximately $116,000. Hedge funds and other institutional investors own 47.06% of the company’s stock.
Eiger BioPharmaceuticals (NASDAQ:EIGR) last issued its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($1.10) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.28) by $0.18. research analysts anticipate that Eiger BioPharmaceuticals will post -5.08 EPS for the current fiscal year.
WARNING: This article was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/12/11/eiger-biopharmaceuticals-inc-eigr-given-consensus-recommendation-of-buy-by-brokerages.html.
About Eiger BioPharmaceuticals
Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.
Receive News & Ratings for Eiger BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.